LCD L38814: MolDX: Minimal Residual Disease Testing for Cancer — Noridian
Policy LCD-L38814 · Oncology
Billing impact from new MolDX LCD for cancer tests.
Code intelligence
C92.00 reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code C92.00.
Normal code riskView ICD-10 detail
Signal breakdown
5 shown · 5 total in platform
Risk: Normal
0
Critical
0%
0
High
0%
5
Routine
100%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
Routine
LCD L38070: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies — CGS
Policy LCD-L38070 · Clinical Laboratory
New LCD to improve billing for myeloid malignancy testing.
LCD L38125: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies — Noridian
Policy LCD-L38125 · Oncology
New LCD for myeloid malignancies requires billing team review.
LCD L38123: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies — Noridian
Policy LCD-L38123 · Oncology
New LCD impacts myeloid malignancies testing billing.
LCD L39923: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Noridian
Policy LCD-L39923 · Hematology
Changes in billing for myeloproliferative neoplasms testing ahead.
Audit documentation
Building an audit file that includes C92.00?
The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Oncology audit pack — $349One-time purchase · not a subscription